Selective THR Beta-1 Agonists for Metabolic Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thyroid hormone receptor (THR) ligands lack selectivity for THR β1, leading to cardiac side effects, making them unsuitable for treating obesity and dyslipidemia, while specific THR β agonists are needed to avoid these toxicities and harness beneficial effects.
Innovation Solution
Development of novel compounds defined by a specific general formula that act as selective THR β1 agonists, designed to regulate gene expression and treat obesity and dyslipidemia without cardiac side effects, including their synthesis, tautomeric forms, pharmaceutically acceptable salts, and pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If natural thyroid hormone T3 is administered to lower plasma cholesterol and triglyceride levels, then beneficial metabolic effects are achieved, but cardiac side effects such as tachycardia and arrhythmia occur
Solution Approach 1:
The invention segments the thyroid hormone receptor system into two distinct isoforms (THRα and THRβ) and develops ligands that selectively target only the THRβ isoform. This segmentation allows the therapeutic effects on metabolism to be achieved while avoiding activation of THRα in cardiac tissue, thereby eliminating cardiac side effects.
Solution Approach 2:
The patent applies local quality by creating ligands with differential affinity for different receptor isoforms. The compounds are designed to have high selectivity for THRβ1 in liver and adipose tissue while showing minimal activity at THRα in cardiac tissue, thereby achieving tissue-specific therapeutic effects without systemic toxicity.
2Quantity of substance
If T3 is used to treat hypercholesterolemia and obesity, then metabolic parameters improve, but cardiac toxicity prevents therapeutic use
Solution Approach 1:
The invention segments the thyroid hormone receptor system into two distinct isoforms (THRα and THRβ) and develops ligands that selectively target only the THRβ isoform. This segmentation allows the therapeutic effects on metabolism to be achieved while avoiding activation of THRα in cardiac tissue, thereby eliminating cardiac side effects.
Solution Approach 2:
The patent applies local quality by creating ligands with differential affinity for different receptor isoforms. The compounds are designed to have high selectivity for THRβ1 in liver and adipose tissue while showing minimal activity at THRα in cardiac tissue, thereby achieving tissue-specific therapeutic effects without systemic toxicity.
3Reliability
If THR β1 selective agonists are developed to avoid cardiac side effects, then therapeutic safety improves, but compound selectivity and activity must be optimized
Solution Approach 1:
The patent employs parameter changes by systematically modifying the chemical structure of thyroid hormone analogs, particularly at positions 2 and 4 of the inner phenol ring. Specific substitutions (such as fluorine atoms, hydroxyl groups, and various alkyl groups) are introduced to fine-tune the ligand's affinity for THRβ1 versus THRα, achieving optimal selectivity ratios.
Solution Approach 2:
The patent applies local quality by creating ligands with differential affinity for different receptor isoforms. The compounds are designed to have high selectivity for THRβ1 in liver and adipose tissue while showing minimal activity at THRα in cardiac tissue, thereby achieving tissue-specific therapeutic effects without systemic toxicity.
Data Source
AI summary
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta(TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.